Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic…
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Â Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory…